Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ATG-022 |
Synonyms | |
Therapy Description |
ATG-022 is an antibody-drug conjugate (ADC) targeting CLDN18.2, which potentially inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 1143). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ATG-022 | ATG 022|ATG022 | CLDN18.2 Antibody 18 | ATG-022 is an antibody-drug conjugate (ADC) targeting CLDN18.2, which potentially inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 1143). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05718895 | Phase I | ATG-022 | A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors (CLINCH) | Recruiting | AUS | 1 |